[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

Year

Day

February 20, 2020
Original Investigation

Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial

Abstract Full Text
JAMA Oncol. Published online February 20, 2020. doi:10.1001/jamaoncol.2019.6584

This nonrandomized phase 1/2 clinical trial evaluates the use of trabectedin in combination with low-dose radiotherapy for treating metastatic soft-tissue sarcomas in adult patients.

Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer: A Nonrandomized Controlled Trial

Abstract Full Text
JAMA Oncol. Published online February 20, 2020. doi:10.1001/jamaoncol.2019.6731

This phase 1 nonrandomized controlled trial assesses the safety and tolerability of programmed cell death 1 inhibition concurrently with definitive chemoradiotherapy compared with programmed cell death 1 inhibition and radiotherapy in patients with non–small cell lung cancer.

JAMA Oncology Clinical Challenge

Erythematous Patch With Central Papules on the Forehead of a Middle-aged Woman

Abstract Full Text
has active quiz
JAMA Oncol. Published online February 20, 2020. doi:10.1001/jamaoncol.2019.6289

A middle-aged woman presented with a tender, pruritic, 4-cm erythematous patch on the forehead that enlarged over the course of 6 weeks. What is your diagnosis?

Viewpoint

Will Medical Preprints Change Oncology Practice?

Abstract Full Text
JAMA Oncol. Published online February 20, 2020. doi:10.1001/jamaoncol.2019.5972

This Viewpoint discusses limitations of preprints and how they may change oncology practice and research.

Comment & Response

Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer

Abstract Full Text
JAMA Oncol. Published online February 20, 2020. doi:10.1001/jamaoncol.2019.6859

Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer

Abstract Full Text
JAMA Oncol. Published online February 20, 2020. doi:10.1001/jamaoncol.2019.6865

Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer—Reply

Abstract Full Text
JAMA Oncol. Published online February 20, 2020. doi:10.1001/jamaoncol.2019.6868
February 13, 2020
Original Investigation

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

Abstract Full Text
JAMA Oncol. Published online February 13, 2020. doi:10.1001/jamaoncol.2019.6650

This analysis of data from an ongoing open-label adaptively randomized phase 2 platform trial examines the efficacy of adding pembrolizumab to standard neoadjuvant chemotherapy in patients with early-stage, high-risk, ERBB2-negative breast cancer.

HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer

Abstract Full Text
has audio
JAMA Oncol. Published online February 13, 2020. doi:10.1001/jamaoncol.2019.6496

This study examines the development and outcomes of men with the HSD3B1 genotype receiving treatment for metastatic prostate cancer.

Brief Report

Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online February 13, 2020. doi:10.1001/jamaoncol.2019.6486

This open-label, multicenter, phase 3 trial conducted in Italy assesses 5-year relapse-free survival to evaluate the noninferiority of 3 months (experimental arm) vs 6 months (control arm) of standard doses of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine plus oxaliplatin) adjuvant chemotherapy in patients with high-risk stage II resected colorectal cancer enrolled in the TOSCA trial.

Review

An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review

Abstract Full Text
JAMA Oncol. Published online February 13, 2020. doi:10.1001/jamaoncol.2019.5963

This narrative review discusses the key studies that have established the frequency and types of germline mutations in pancreatic ductal adenocarcinoma and implications for family members, strategies for genetic counseling, and treatment options for individuals with known germline mutations.

Viewpoint

New Graphic Tobacco Warnings and the First Amendment

Abstract Full Text
JAMA Oncol. Published online February 13, 2020. doi:10.1001/jamaoncol.2019.5975

This Viewpoint descibes a new proposed US Food and Drug Administration rule that would require graphic warnings for cigarette packages and advertisements and discusses the legality of the rule compared with a previous attempt to implement a similar set of graphic warnings on these products.

JAMA Oncology Patient Page

Brachytherapy

Abstract Full Text
free access
JAMA Oncol. Published online February 13, 2020. doi:10.1001/jamaoncol.2019.5882

This Patient Page describes the use of brachytherapy (internal radiation) for the treatment of cancer and its delivery, adverse effects, and indications.

Comment & Response

Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer

Abstract Full Text
JAMA Oncol. Published online February 13, 2020. doi:10.1001/jamaoncol.2019.6706

Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer

Abstract Full Text
JAMA Oncol. Published online February 13, 2020. doi:10.1001/jamaoncol.2019.6709

Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. Published online February 13, 2020. doi:10.1001/jamaoncol.2019.6712
February 6, 2020
Original Investigation

Association of Maximal Extent of Resection of Contrast-Enhanced and Non–Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma

Abstract Full Text
JAMA Oncol. Published online February 6, 2020. doi:10.1001/jamaoncol.2019.6143

This multicenter cohort study assesses the association of maximal extent of resection of contrast-enhanced and non–contrast-enhanced tumor with survival among patients with newly diagnosed glioblastoma in different molecular subgroups to develop a new road map for cytoreductive surgery.

Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer

Abstract Full Text
JAMA Oncol. Published online February 6, 2020. doi:10.1001/jamaoncol.2019.6400

This population-based cohort study examines the association of germline genetic testing results with locoregional and systemic therapy use in women aged 20 years or older diagnosed with breast cancer.

Research Letter

Random vs Targeted Urine Drug Testing Among Patients Undergoing Long-term Opioid Treatment for Cancer Pain

Abstract Full Text
JAMA Oncol. Published online February 6, 2020. doi:10.1001/jamaoncol.2019.6756

This cohort study assesses the frequency of abnormal urine drug test findings among patients with cancer pain treated with long-term opioid therapy who underwent random and targeted testing.

Viewpoint

An Action Plan for Environmentally Sustainable Cancer Care

Abstract Full Text
JAMA Oncol. Published online February 6, 2020. doi:10.1001/jamaoncol.2019.5364

This Viewpoint exposes the need for environmentally sustainable oncology practices and facilities and evaluates strategies for achieving both.

Invited Commentary

A Common Rule for Resection of Glioblastoma in the Molecular Era

Abstract Full Text
JAMA Oncol. Published online February 6, 2020. doi:10.1001/jamaoncol.2019.6384
Comment & Response

Using Real-world Historical Controls to Evaluate Radiation Dose Escalation in Esophageal Cancer

Abstract Full Text
JAMA Oncol. Published online February 6, 2020. doi:10.1001/jamaoncol.2019.6406

Using Real-World Historical Controls to Evaluate Radiation Dose Escalation in Esophageal Cancer—Reply

Abstract Full Text
JAMA Oncol. Published online February 6, 2020. doi:10.1001/jamaoncol.2019.6412
×